Use of XXXX in pediatric renal transplant recipients.

@entity1 @entity1009 @entity229 @entity205 @entity1011 @entity1292
@entity205 and @entity229 were used in combination to produce immunosuppression in 18 pediatric recipients of renal allografts. Ten @entity1 received cadaveric kidneys and eight received kidneys from living related donors. With a mean follow-up of 16.5 months (range 7 to 33 months), the @entity1 survival rate is 100% (18 of 18) and the graft survival rate is 83% (15 of 18). Two grafts were lost for nonimmunologic reasons. Currently the group mean (+/- SE) serum @entity1011 concentration is 1.22 +/- 0.11 mg/dl and @entity1011 clearance is 69.3 +/- 4.79 ml/ @entity1009 .73 m2. @entity205 nephrotoxicity has not caused irreversible allograft injury nor led to graft loss in this population. The incidence of treated rejection episodes has been 39% (seven of 18). Only 39% (seven of 18) of @entity1 have required hospital readmissions since the initial transplant discharge. There have been no @entity1292 . In the 15 @entity1 with functioning grafts, some linear growth has occurred in 10 of 11 prepubertal and two of four postpubertal @entity1 . @entity205 and @entity229 have constituted a safe, efficacious immunosuppressive regimen for pediatric renal allograft recipients. Longer follow-up will be necessary to confirm whether these advantages persist beyond 2 years.
